LMN 201
Alternative Names: LMN-201; LMN-Cdiff01Latest Information Update: 28 Sep 2024
Price :
$50 *
At a glance
- Originator Lumen Bioscience
- Class Antibacterials; Enzymes; Proteins
- Mechanism of Action Bacterial toxin modulators; Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Clostridium difficile infections
- Preclinical Crohn's disease; Ulcerative colitis
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for phase-I development in Clostridium-difficile-infections(In volunteers) in Australia (PO, Capsule)
- 28 Sep 2024 No recent reports of development identified for phase-I development in Clostridium-difficile-infections(Prevention, In volunteers) in Australia (PO, Capsule)
- 29 Aug 2024 Phase-II/III clinical trials in Clostridium difficile infections (Prevention) in USA (PO) (NCT05330182)